Tnfrsf10b-flox Mouse
一般名
Tnfrsf10b-flox
製品ID
S-CKO-06384
背景情報
C57BL/6JCya
系統ID
CKOCMP-21933-Tnfrsf10b-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Tnfrsf10b-flox Mouse（カタログ番号S-CKO-06384）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Tnfrsf10b-flox
系統ID
CKOCMP-21933-Tnfrsf10b-B6J-VA
遺伝子名
製品ID
S-CKO-06384
遺伝子別名
MK, DR5, Ly98, KILLER, TRICKB, TRAILR2, TRICK2A, TRICK2B
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 14
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000022663
NCBIトランスクリプトID
NM_020275
ターゲット領域
Exon 2
有効領域の大きさ
~1.3 kb
遺伝子研究の概要
Tnfrsf10b, also known as TRAIL-R2 or DR5, codes for a pro-apoptotic receptor activated by TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) and is involved in apoptosis-related pathways, playing a crucial role in immune surveillance against virus-infected or transformed cells [1,7].
In chronic lymphocytic leukemia (CLL), del(8p) is associated with poor prognosis and fludarabine resistance, and TNFRSF10B is haploinsufficient in 91% of del(8p) CLL cases, involved in modulating fludarabine-induced cell death [1].
In non-small cell lung cancer, certain TNFRSF10B polymorphisms and haplotypes are associated with an increased risk of death [2].
In diabetic kidney disease, TNFRSF10B expression is increased in podocytes, and TRAIL/DR5 signaling via TNFRSF10B promotes podocyte PANoptosis, with podocyte-specific deletion of TNFRSF10B alleviating podocyte and glomerular injury in diabetic mice [3].
In non-small cell lung cancer cells, YIPF2 promotes chemotherapeutic agent-mediated apoptosis by enhancing TNFRSF10B recycling to the plasma membrane [4].
In lung adenocarcinoma, TNFRSF10B mRNA is preferentially expressed in EGFR wild-type tumors, and strong TRAIL-R2 (encoded by TNFRSF10B) expression predicts a poor prognosis [5].
In HPV-positive head and neck squamous cell carcinomas, combining a death agonist antibody against TNFRSF10B with birinapant enhances anti-tumor activity [6].
Hepatitis B virus-triggered autophagy targets TNFRSF10B for degradation, limiting the TNFSF10/TRAIL response, allowing virus-infected cell survival [7].
In conclusion, Tnfrsf10b is essential for apoptosis-related biological processes. Studies using gene-knockout or cell-specific knockout models in various diseases such as leukemia, lung cancer, and diabetic kidney disease have revealed its role in disease prognosis, response to treatment, and disease-related cellular processes. Understanding Tnfrsf10b's functions through these models provides insights into disease mechanisms and potential therapeutic targets.
References：
1. Jondreville, Ludovic, Dehgane, Lea, Doualle, Cecile, Susin, Santos A, Nguyen-Khac, Florence. 2023. del(8p) and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia. In Leukemia, 37, 2221-2230. doi:10.1038/s41375-023-02035-3. https://pubmed.ncbi.nlm.nih.gov/37752286/
2. Schabath, Matthew B, Giuliano, Anna R, Thompson, Zachary J, Beg, Amer A, Haura, Eric B. 2013. TNFRSF10B polymorphisms and haplotypes associated with increased risk of death in non-small cell lung cancer. In Carcinogenesis, 34, 2525-30. doi:10.1093/carcin/bgt244. https://pubmed.ncbi.nlm.nih.gov/23839018/
3. Lv, Zhimei, Hu, Jinxiu, Su, Hong, Shen, Ning, Wang, Rong. 2024. TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease. In Kidney international, 107, 317-331. doi:10.1016/j.kint.2024.10.026. https://pubmed.ncbi.nlm.nih.gov/39571905/
4. Wang, Yingying, Guo, Sen, Li, Dongmei, Su, Ling, Liu, Xiangguo. 2020. YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells. In Cell death & disease, 11, 242. doi:10.1038/s41419-020-2436-x. https://pubmed.ncbi.nlm.nih.gov/32303681/
5. Chang, Wei-Chin, Yeh, Yi-Chen, Ho, Hsiang-Ling, Chou, Teh-Ying. 2022. Deep exploration of immune function in EGFR wild-type and mutated lung adenocarcinomas by gene expression profiling: role of TRAIL-R2 (TNFRSF10B) in patient treatment and outcome. In Human pathology, 126, 9-18. doi:10.1016/j.humpath.2022.05.004. https://pubmed.ncbi.nlm.nih.gov/35550831/
6. An, Yi, Jeon, Jun, Sun, Lillian, Van Waes, Carter, Chen, Zhong. 2021. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas. In Scientific reports, 11, 6392. doi:10.1038/s41598-021-85589-5. https://pubmed.ncbi.nlm.nih.gov/33737574/
7. Shin, Gu-Choul, Kang, Hong Seok, Lee, Ah Ram, Kim, Kyun-Hwan. 2016. Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response. In Autophagy, 12, 2451-2466. doi:. https://pubmed.ncbi.nlm.nih.gov/27740879/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。